Fulvestrant Injection, Solution
Product Images NDC 70710-1688

Product Visual Gallery

This gallery contains 17 technical images submitted to the FDA as part of the official labeling for Fulvestrant (NDC 70710-1688). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Zydus Pharmaceuticals Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (297c22a2 0a7d 4b35 9f11 31a7c75501b8 01)

An instructional illustration showing the proper removal of a cap from a vial or container, with a hand twisting and pulling the cap off. Adjacent images label parts of the cap and vial components with letters A, B, and C, indicating specific features or sections relevant to product preparation or usage.*

FDA Label Image

Image (297c22a2 0a7d 4b35 9f11 31a7c75501b8 02)

An instructional illustration showing how to remove a protective cap from a vial or syringe. The image includes a hand pulling the cap upward and a labeled diagram with parts A, B, and C highlighting components of the vial or syringe.*

FDA Label Image

Image (297c22a2 0a7d 4b35 9f11 31a7c75501b8 03)

An instructional illustration showing two hands preparing an injection syringe. One hand holds the syringe barrel and vial, while the other hand pulls off a cap from the needle, indicating a preparation step for intramuscular injection.*

FDA Label Image

Image (297c22a2 0a7d 4b35 9f11 31a7c75501b8 04)

An instructional diagram showing a drawing of an intramuscular injection needle and syringe with an enlarged view of the needle tip, likely illustrating proper technique or needle specifics related to administration of fulvestrant injection.*

FDA Label Image

Image (297c22a2 0a7d 4b35 9f11 31a7c75501b8 05)

Illustration shows a hand holding a syringe with the needle pointing upward and an arrow indicating the removal of the needle cap. This instructional diagram is related to the preparation of FULVESTRANT injection, solution, 50 mg/mL by Zydus Pharmaceuticals USA Inc.*

FDA Label Image

Image (297c22a2 0a7d 4b35 9f11 31a7c75501b8 06)

Chemical structure of fulvestrant, the active ingredient in FULVESTRANT injection solution, 50 mg/mL by Zydus Pharmaceuticals USA Inc.*

FDA Label Image

Image (297c22a2 0a7d 4b35 9f11 31a7c75501b8 07)

This line graph depicts the progression-free survival of patients treated with Fulvestrant 250 mg and 500 mg over approximately 45 months. The y-axis shows the proportion of patients progression free, while the x-axis represents time in months. Two curves compare survival rates between Fulvestrant 250 mg and 500 mg dosages, with corresponding patient numbers at risk listed below for each treatment group.*

FDA Label Image

Image (297c22a2 0a7d 4b35 9f11 31a7c75501b8 08)

A survival curve chart displaying the proportion of patients alive over time (months) for fulvestrant 500 mg and 250 mg doses. The x-axis represents time in months up to 80, and the y-axis shows the proportion of patients alive from 0 to 1. The chart includes risk tables with patient counts at various time points and notes that tick marks indicate censored observations. A legend distinguishes the two dose groups, and a note states no statistical significance due to lack of multiplicity adjustment.*

FDA Label Image

Image (297c22a2 0a7d 4b35 9f11 31a7c75501b8 09)

A Kaplan-Meier curve showing the probability of progression-free survival (PFS) over time in months from randomization for two treatments: Fulvestrant 500 mg and Anastrozole 1 mg. The chart includes patient numbers at risk over time for each treatment group, with Fulvestrant represented by a solid line and Anastrozole by a dashed line.*

FDA Label Image

Image (297c22a2 0a7d 4b35 9f11 31a7c75501b8 10)

A Kaplan-Meier survival curve graph showing progression-free survival probability (%) over time in months. Two treatment groups are compared: fulvestrant plus palbociclib and fulvestrant plus placebo. The graph includes the number of patients at risk at various time points for each group.*

FDA Label Image

Image (297c22a2 0a7d 4b35 9f11 31a7c75501b8 11)

A line graph showing overall survival probability (%) over time (months) comparing two treatment groups: Fulvestrant plus palbociclib and Fulvestrant plus placebo. The graph includes survival curves with the number of patients at risk listed below at various time points up to 54 months.*

FDA Label Image

Image (297c22a2 0a7d 4b35 9f11 31a7c75501b8 12)

A Kaplan-Meier curve displaying progression-free survival probability (%) over time in months for patients treated with fulvestrant plus abemaciclib compared to fulvestrant plus placebo. The graph includes censored observations and patients at risk at various time points for both groups.*

FDA Label Image

Image (297c22a2 0a7d 4b35 9f11 31a7c75501b8 13)

A survival probability Kaplan-Meier curve chart showing survival probability (%) over time in months for patients treated with Fulvestrant plus Abemaciclib versus Fulvestrant plus Placebo. The chart includes censored observations and a table of patients at risk at various time points for both treatment groups.*

FDA Label Image

Image (297c22a2 0a7d 4b35 9f11 31a7c75501b8 14)

A survival plot showing event-free probability over time (months) comparing two groups: Fulvestrant plus Ribociclib (N=484) and Fulvestrant plus Placebo (N=242). The graph includes censoring times and a table listing the number of patients still at risk at different time points from 0 to 26 months.*

FDA Label Image

Image (297c22a2 0a7d 4b35 9f11 31a7c75501b8 15)

A line graph showing event-free probability (%) over time in months for two groups: one receiving Fulvestrant plus Ribociclib (N=484) and the other receiving Fulvestrant plus Placebo (N=242). The graph includes censored data points and a table below listing the number of patients still at risk at various time points up to 48 months.*

FDA Label Image

Pfs Label (297c22a2 0a7d 4b35 9f11 31a7c75501b8 16)

Label for Fulvestrant Injection 250 mg/5 mL (50 mg/mL) solution for intramuscular injection. The label includes dosage strength, administration instructions, storage warning to protect from light, and mentions the product is for prescription use only. Distributed by Zydus Pharmaceuticals USA Inc. with NDC 70710-1688.*

FDA Label Image

Carton Label (297c22a2 0a7d 4b35 9f11 31a7c75501b8 17)

Fulvestrant Injection 250 mg/5 mL (50 mg/mL) prefilled syringe carton from Zydus Pharmaceuticals USA Inc. The label shows the product name, strength, dosage form (injection, solution), and intramuscular route. It contains 2 single-dose prefilled syringes, each with 250 mg/5 mL of fulvestrant, totaling 500 mg. Storage instructions specify refrigeration at 2° to 8°C and protection from light. The carton includes detailed syringe preparation and administration instructions.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.